RMD

ResMed
D

RMD

Arincen97/100B

ResMed EPS (earnings per share) 1993–2027

ResMed's diluted EPS in Q1 FY2027, the three months to 30 September 2026, was 2.92 USD, up 23.2% on the same quarter a year before. ResMed's diluted earnings per share over the last twelve months were 10.95 USD, up 12.1% on the twelve months before. In fiscal year 2026 they were 10.40 USD, up 9.4% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 202610.95+12.08%10.99
FY202630 Jun 202610.40+9.36%10.44
FY202530 Jun 20259.51+37.43%9.55
FY202430 Jun 20246.92+13.63%6.94
FY202330 Jun 20236.09+14.91%6.12
FY202230 Jun 20225.30+63.58%5.34
FY202130 Jun 20213.24-24.12%3.27
FY202030 Jun 20204.27+52.50%4.31
FY201930 Jun 20192.80+27.85%2.83
FY201830 Jun 20182.19-8.75%2.21
FY201730 Jun 20172.40-3.61%2.42
FY201630 Jun 20162.49+0.81%2.51
FY201530 Jun 20152.47+3.35%2.51
FY201430 Jun 20142.39+13.81%2.44
FY201330 Jun 20132.10+22.81%2.15
FY201230 Jun 20121.71+18.75%1.75
FY201130 Jun 20111.44+17.07%1.49
FY201030 Jun 20101.23+29.47%1.26
FY200930 Jun 20090.95+35.71%0.97
FY200830 Jun 20080.70+62.79%0.72
FY200730 Jun 20070.43-25.86%0.43
FY200630 Jun 20060.58+26.09%0.61
FY200530 Jun 20050.46+12.20%0.47
FY200430 Jun 20040.41+24.24%0.43
FY200330 Jun 20030.33+17.86%0.35
FY200230 Jun 20020.28+220.00%0.29
FY200130 Jun 20010.09-48.53%0.09
FY200030 Jun 20000.17+30.77%0.19
FY199930 Jun 19990.13+47.56%0.14
FY199830 Jun 19980.09+38.09%0.09
FY199730 Jun 19970.06+59.50%0.06
FY199630 Jun 19960.040.00%0.04
FY199530 Jun 19950.04+77.78%0.04
FY199430 Jun 19940.02+50.00%0.02
FY199330 Jun 19930.02—0.02

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about ResMed's EPS

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.